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greater patient–physician trust and 
provide more opportunity for detecting 
warning signs indicative of malignant 
transformation in plexiform neurofibro-
mas, and (iii) NF-1 patient anxiety regard-
ing the unpredictable evolution of their 
disease could be alleviated partially by 
quantifiable assessment of their risk or 
surveillance screening in identified high-
risk populations. Furthermore, the authors 
note that the quantitative nature of the 
NF-1Score can be utilized in clinical trials: 
in determining patient inclusion criteria, 
quantifying disease severity, or categoriz-
ing participants by risk level for MPNSTs.
Adult patients judged to have “asymp-
tomatic” or mild NF-1 disease are not 
strongly encouraged to attend clinics in 
adulthood under current treatment pro-
tocols (Ferner et al., 2007); however, the 
NF-1Score parameters suggest that a lack 
of cutaneous features of NF-1 may place 
the patient at even greater risk for unfa-
vorable outcomes. This study may help 
to identify a population for which contin-
ued follow-up is clearly warranted. Adult 
NF-1 patients who decline regular care 
are encouraged to maintain familiarity 
with dangerous warning signs indicative 
of shifting neurofibroma status, includ-
ing intense/long-lasting pain, alteration 
in the consistency of a neurofibroma 
from soft to hard, and rapid neurofibroma 
growth (Ferner et al., 2007). Patients with 
high NF-1Scores could be instructed to 
pay special attention to these guidelines. 
Indeed, one of the recent foci in improving 
medical care has been to facilitate patient 
empowerment in disease management. 
A successful example of this has been the 
distribution of melanoma mole self-skin 
test cards to the public to aid in aware-
ness of the risk factors for melanoma and 
to instruct in self-examination. A similar 
card could be devised for NF-1 patients 
describing the neurofibroma “self-exam,” 
in addition to a list of risk factors for 
internal neuro fibromas, directing patients 
to contact their physicians if they meet 
three of the four predictive factors.
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Clinical Implications
•  The NF-1Score allows surveillance screening in identified high-risk populations.
•  NF-1 patients’ anxiety about the unpredictable nature of their disease may be 
alleviated partially by a quantifiable assessment of risk.
•  More frequent visits could promote patient–physician trust and provide 
opportunities for detecting signs of malignant transformation.
•  MRI scans could identify tumors requiring further PET scan monitoring.
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Melanoma is the most dangerous type of skin cancer, with notorious resistance 
to current chemotherapy and immunotherapy. In this issue, Hiscutt et al. report 
on the prognostic significance of X-linked inhibitor of apoptosis protein (XIAP) 
in melanoma. The finding that XIAP inhibition significantly increases endoplas-
mic reticulum stress-mediated apoptosis in melanoma cells suggests that XIAP 
is a potential therapeutic target for melanoma therapy.
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XIaP as a potential biomarker  
of melanoma
Skin cancer is one of the most 
common human malignancies, and 
its incidence is rising globally at an 
alarming rate. Basal cell carcinoma, 
squamous cell carcinoma, and mela-
noma are three major forms of skin 
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correlation of XIAP expression with 
prognostic variables or clinical aggres-
siveness of melanomas is important.
Hiscutt et al. (2010, this issue) report 
the prognostic and therapeutic signifi-
cance of XIAP in melanoma. Through 
the investigation of XIAP expression 
in 55 clinical patient samples, con-
sisting mainly of superficial spread-
ing melanoma, the investigators fre-
quently found elevated expression of 
XIAP in late-stage primary cutaneous 
melanoma and a significant difference 
in the percentage of XIAP-positive 
cells between patient samples from 
stage II melanomas and samples from 
benign nevi. By determining XIAP 
levels in a range of thin and thick pri-
mary tumors, the investigators found a 
trend in which increased XIAP expres-
sion was associated with increased 
Breslow thickness. This report com-
plements observations made by oth-
ers (Emanuel et al., 2008; Kluger et 
al., 2007). Moreover, the positive cor-
relation between upregulated XIAP 
expression and disease stage indicates 
that XIAP may be a useful biomarker 
in assessing melanoma metastases.
critical role of endoplasmic reticulum 
stress in melanoma
The endoplasmic reticulum (ER) is a 
central organelle for protein folding 
and protein maturation. When the ER’s 
capacity to process proteins is exceed-
ed, the accumulation of unfolded and 
misfolded proteins can lead to cellular 
stress responses mediated by the ER, 
which play an important role in many 
diseases including cancer (Kim et al., 
2008). To cope with ER stress, cells 
activate a series of signal-transduction 
events known as the unfolded protein 
response (UPR), which inhibits new 
protein synthesis, upregulates chap-
erones, and increases protein deg-
radation. The UPR initially provides 
prosurvival mechanisms by which the 
cells can maintain ER homeostasis, 
but a prolonged UPR under severe ER 
stress may lead to cell death (Kim et 
al., 2008; Xu et al., 2005).
In malignancies, stressful condi-
tions in the tumor microenvironment 
such as low oxygen supply, nutrient 
deprivation, and pH changes activate 
a range of cellular stress response 
pathways. In their drive to survive, 
cancer cells hijack many normal pro-
cesses such as cell cycle signaling, 
angiogenesis, glucose metabolism, 
and the UPR. Recent studies have 
shown that the UPR plays an impor-
tant role in melanoma development 
and drug resistance (Healy et al., 
2009).
How do cancer cells escape death 
under prolonged ER stress conditions? 
One possible mechanism is that the 
signaling cascades that enhance ER 
and cellular function are perpetuated, 
whereas those that lead to apoptosis 
are suppressed. For example, a number 
of studies have reported that GRP78 
(an essential chaperone that assists pro-
tein folding and is quickly upregulated 
in response to ER stress) is increased 
in several cancer types. To investigate 
whether GRP78 expression correlates 
with development and progression of 
human melanoma, Zhuang et al. (2009) 
analyzed GRP78 levels in nevi, primary 
melanomas, and melanoma metastases 
from 171 patients. GRP78 expression 
correlated positively with increasing 
tumor thickness and with increasing 
dermal tumor mitotic index. Although 
most melanomas exhibit ER stress and 
UPR, even at early stages of develop-
ment, they are insensitive to ER stress-
induced apoptosis. Under laboratory 
conditions of extreme ER stress induced 
by tunicamycin or thapsigargin, mela-
noma cell lines remain relatively resis-
tant to apoptosis even though varying 
degrees of apoptosis occur in normal 
melanocytes and fibroblasts (Jiang et 
al., 2007a), implying that protective 
mechanisms against ER stress-mediated 
apoptosis are active in the melanomas.
Melanoma’s ability to adapt to 
ER stress and to escape apoptosis 
prompts two anticancer strategies. The 
first involves inhibiting components of 
the UPR, preventing tumors growing 
under stressful conditions from cop-
ing with the stress. The second is to 
restore or enhance ER stress-induced 
cell death. Hiscutt et al. (2010) dem-
onstrate that XIAP depletion signifi-
cantly increases ER stress-induced 
apoptosis of melanoma cells in a 
caspase-dependent manner. In this 
study, melanoma cell line A375 cells 
stably expressing XIAP shRNA were 
cancer; among these, melanoma 
occurs less frequently, but it causes 
the majority of skin cancer–related 
deaths. In fact, melanoma is one of 
the most aggressive human cancers. 
Melanoma arises from melanocytes, 
which are specialized pigmented 
cells found predominantly in the skin. 
Although melanoma can be cured by 
surgical resection in its early stages, 
it is unresponsive to treatment once 
it has progressed to the metastatic 
stage, leading to a poor prognosis. 
Resistance to apoptosis is likely the 
mechanism underlying melanoma’s 
drug resistance because most chemo-
therapeutic drugs exert their function 
by inducing cell apoptosis. Therefore, 
new therapeutic strategies are urgent-
ly needed. Discoveries in melanoma 
biology have provided greater under-
standing at the cellular, molecular, 
and genetic levels (Chin et al., 2006; 
Gray-Schopfer et al., 2007), and 
these advances are being exploited 
to provide targeted drugs and new 
therapeutic approaches.
The X-linked inhibitor of apopto-
sis protein (XIAP) is a member of the 
inhibitor of apoptosis protein family. 
XIAP inhibits apoptosis by binding to 
caspase-3, caspase-7, and caspase-9, 
thereby inhibiting their activation 
(Schimmer et al., 2006). Accumulating 
evidence suggests that deregulation 
of XIAP can result in cancer develop-
ment, neurodegenerative disorders, 
and autoimmunity. Elevated XIAP 
expression has been proposed to 
serve as a tumor marker. Specifically, 
experimental data indicate that XIAP 
expression correlates with the patho-
genesis of melanoma (Kluger et al., 
2007). The upregulation of XIAP has 
been found in a number of melanoma 
cell lines, as well as in primary cutan-
eous and metastatic melanoma tissues 
(Emanuel et al., 2008). XIAP over-
expression is believed to be associat-
ed with chemoresistance in a number 
of human malignancies. However, to 
date, only a few studies have inves-
tigated XIAP expression levels in 
clinically obtained melanoma tissue 
samples. To better understand the 
role of XIAP in malignant melanoma 
and to validate XIAP as a therapeutic 
target, in-depth investigations of the 
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generated, and their sensitivity to 
apoptosis was analyzed in response 
to 24-hour treatments with clinically 
achievable concentrations of fenretin-
ide, bortezomib, or thapsigargin. XIAP 
knockdown resulted in a significant 
increase in apoptosis in response to 
these ER stress-inducing drugs when 
compared with control cells. On the 
other hand, XIAP inhibition did not 
promote apoptosis of A375 or CHL-1 
cells treated with a current melano-
ma therapeutic drug, temozolomide 
(a DNA damage reagent). These data 
strongly suggest that XIAP’s apopto-
sis-inhibiting effect specifically helps 
melanoma to escape ER stress-medi-
ated cell death (Figure 1). Therefore, 
XIAP depletion or inhibition of XIAP 
function by small molecules could 
be an attractive strategy to enhance 
ER stress-mediated apoptosis in mela-
noma. Because the adaptation to ER 
stress is a driver of malignancy and 
resistance to therapy in human mela-
noma, XIAP may be an important tar-
get for treating metastatic melanoma 
and may be a major contributor to 
melanoma’s observed resistance to 
current clinical drugs.
Potential link between the ras/ 
raf pathway and XIaP
Several of the crucial cell-signaling 
pathways that regulate cell survival, 
proliferation, and motility have been 
identified as highly important in 
melanoma (Chin et al., 2006; Gray-
Schopfer et al., 2007). For example, 
the Ras/Raf/MEK/ERK and phospho ino-
sitide-3-OH kinase (PI(3)K) pathways 
are hyperactivated in high propor-
tions of melanomas. In addition, Ras 
and Raf mutations, which activate 
the Ras/Raf/MEK/ERK pathway, are 
closely related to the resistance to ER 
stress-induced apoptosis in melano-
ma (Jiang et al., 2007b). Meanwhile, 
Figure 1. Unfolded protein response and the role of XIaP in er stress–mediated apoptosis in melanoma 
cells. Cyto c, cytochrome c; ER, endoplasmic reticulum; XIAP, X-linked inhibitor of apoptosis protein.
Clinical Implications
•  XIAP expression and melanoma progression are significantly correlated.
•  XIAP inhibition significantly increases fenretinide- and bortezomib-
induced apoptosis of metastatic melanoma cells.
•  XIAP is potentially a useful prognostic marker, as well as an effective 
therapeutic target for melanoma therapy.
upregulation of the antiapoptotic pro-
teins is another mechanism critical 
for the protection of melanoma cells 
against ER stress-induced apoptosis. 
Because recent reports have shown 
that XIAP participates in Ras/Raf sig-
naling (Dogan et al., 2008), it is useful 
to investigate the correlation between 
XIAP upregulation and the presence of 
Ras and Raf mutations in melanoma. 
Hiscutt et al. (2010) report no signifi-
cant correlation between N-RasG61A or 
B-RafV600E mutational status and the 
level of XIAP expression in clinical 
samples. Further investigation will be 
needed to understand whether other 
rare activating mutations influencing 
Ras/Raf signaling are associated with 
XIAP expression.
Perspectives
Melanoma is an aggressive dis-
ease with high metastatic potential 
and notoriously high resistance to 
chemotherapeutic agents. With the 
increasing recognition of an associa-
tion between ER stress and melanoma, 
enhancing ER stress-mediated cell 
death is emerging as a new therapeu-
tic approach for metastatic melanoma. 
The work by Hiscutt and colleagues 
imparts important insights into the 
correlations among XIAP expression 
and disease stage, RAS/RAF mutation-
al status, and clinical outcome. The 
fact that inhibition of XIAP increases 
the sensitivity of metastatic melanoma 
cells to ER stress-induced death gen-
erates an impetus for targeting XIAP 
in melanoma chemoresistance. XIAP 
inhibitors may become useful in drug 
combination therapy for the treatment 
of metastatic melanoma.
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